Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Sparx Bioscience Limited

Abbvie Deutschland Gmbh and Co Kg

Hongyu H Zhao

Ying Wang

Huan-Qiu Li

Charles W Hutchins

Wilhelm Amberg

Udo Lange

Anil Vasudevan

Frauke Pohlki

Stevan Wakefield Djuric

Yanbin Lao

Jason T Brewer

Wilfried Martin Braje

Sean Colm Turner

Alan Frank Gasiecki

Irini Akritopoulou-Zanze

Shashank Shekhar

Noel S Wilson

Justin D Dietrich

Ana-Lucia Relo

Dennie S Welch

Min Zhang

Albert Wayne Kruger

Jorge Gandarilla

Irini Zanze

Huanqiu Li

Christina M Thompson

Michael Ochse

Michael Michaelides

Richard F Clark

Alan S Florjancic

Marina Pliushchev

Michael L Curtin

Zhiqin Ji

Ramzi Farah Sweis

Guidong Zhu

Jingdong Ye

Jingdong Qin

Jichun Ma

Mariazel Torrent

Jason Brewer

Justin Dietrich

Ying X Wang

Antibodies binding to human claudin 18.2 (CLDN 18.2) and bispecific antibodies binding to both human CLDN 18.2 and PD-L1, pharmaceutical compositions comprising such, and methods of using such for treating target diseases including cancer.

Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (PD-L1)

Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A, A, A, A, A, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.

Indane inhibitors of EED and methods of their use

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy

The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.

Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.

Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy

The present invention relates to 4,5-dihydropyrazole derivatives of the formula (I) and physiologically tolerated salts thereof which are GlyT1 inhibitors. The invention further relates to pharmaceutical compositions comprising such 4,5-dihydropyrazole derivatives, and the use of such 4,5-dihydropyrazole derivatives for therapeutic purposes.

4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy

The present invention relates to isoindoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such isoindoline derivatives, and the use of such isoindoline derivatives for therapeutic purposes.

Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Growing community of inventors

Libertyville, IL, United States of America

Hongyu H Zhao